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DRUG DEVELOPMENT – TRANSLATING BASIC RESEARCH INTO NEW 
MEDICINES – AND THIS ISSUE OF IPLR 
TOMMY THOMPSON 
FORMER SECRETARY 
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
 
 
 I was privileged to serve as U.S. Secretary of Health and Human 
Services (HHS) from 2001-2005, appointed by George W. Bush.  HHS 
oversees the Food and Drug Administration (FDA) and the National Institutes 
of Health (NIH).  NIH is the main agency in the U.S. responsible for funding 
biomedical research—largely in our universities.  During and after my tenure 
at HHS, I have seen exciting advances in biomedical and pharmaceutical 
research, including the development of many new medicines, and the 
sequencing of the human genome.  This is an exciting time in history, where 
we now know more about human biology and are better positioned than ever 
before to develop new medicines.  We are also seeing increased innovation and 
collaboration between universities and industrial partners, to address unmet 
medical needs.  These scientists are attempting to bridge the large gap—
referred to as the “valley of death”—between basic research discoveries in 
academic labs, and drugs in the clinic.  NIH grant funding is increasingly being 
used to translate basic research into the next generation of therapeutics, 
effectively bridging this gap.  This evolutionary change in how drugs are 
developed will not be without its new challenges, and this issue of the 
Marquette Intellectual Property Law Review (IPLR) discusses many of them: 
patenting of biologics-based drugs, drug repositioning in academic research 
labs, access to clinical trial data, and international IP issues surrounding access 
to medicines.  Innovation in the science of drug development will inevitably be 
coupled to public policy debate that shapes the legal and regulatory structures 
that support these advances.  The articles presented herein will further this 
important dialog. 
